 Chimerix Inc NASDAQ: CMRX reports topline results from the first cohort n12 of its Phase 23 study evaluating DSTAT in hospitalized patients with Acute Lung Injury ALI and COVID-19 infection. The primary endpoint of the study is survival without the need for mechanical ventilation through day 28. 